Analytical evaluation of the Dade Behring Dimension RxL automated N-terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010

Clinical Chemistry and Laboratory Medicine

Volumn 43, Issue 11, 2005, Pages 1263-1273

  Di Serio, Francesca ^a,b   Ruggieri, Vincenzo ^a   Varraso, Lucia ^a   De Sario, Rosalisa ^a   Mastrorilli, Angela ^a   Pansini, Nicola ^a  

^a POLICLINICO   (Italy)

^b NONE   (Italy)

Author keywords

Brain natriuretic peptide (BNP); Heart failure; N terminal proBNP (NT proBNP); Natriuretic peptides

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HEPARIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

AGED; ANALYTICAL PARAMETERS; ARTICLE; AUTOMATION; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FREEZING; HEART FAILURE; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; THAWING;

ADULT; AGING; AUTOMATION; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEX CHARACTERISTICS;

EID: 27744524283     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2005.217     Document Type: Article

References (38)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, TX: American Heart Association, 2004.
2. Hunt SA, Baker DW, Chin MH, Feldmanmd AM, Ganiats TG, Gregoratos G, et al. ACC/AHA guidelines for evaluation and management of chronic heart failure in the adult: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104:2996-3007.
3. Agency for Health Care Policy and Research. Heart failure evaluation and care of patients with left ventricular systolic dysfunction. Rockville, MD: Agency for Health Care Policy and Research Agency for Health Care Policy and Research, 1994.
4. Hobbs FD, Jones MI, Allan TF, Wilson S, Tobias R. European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF). Eur Heart J 2004;21:1877-87.
5. Lainchbury JG, Campbell E, Framtom CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003;42:728-35.
6. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;335:9-13.
7. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med 1999;134:437-44.
8. Mair J, Hammer-Lercher A, Puschendorf D. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88.
9. Remme WY, Swedberg K. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
10. Doust JA, Pietrzak E, Dobson A, Glasziou PP. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005;330:1-9.
11. Muller C, Laule-Kilian K, Christ A, Staub D. The use of B-type natriuretic peptide in the diagnosis of acute dyspnoea. Clin Lab 2005;51:5-9.
12. Pfister R, Schneider CA. Natriuretic peptides BNP and NT-proBNP: established laboratory markers in clinical practice or just perspectives? Clin Chim Acta 2004;349: 25-38.
13. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr, Francis GS, et al. BNP consensus panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004;10:1-30.
14. Jernberg T, James S, Lindahl B, Johnston N, Stridsberg M, Venge P, et al. Natriuretic peptides in unstable coronary disease. Eur Heart J 2004;25:1486-93.
15. Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol 2004;44:740-9.
16. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004;50:33-50.
17. Wu AH, Packer M, Smith A, Bijou R, Fink D, Mair J, et al. Analytical and clinical evaluation of the Bayer Advia Centaur automated B-type natriuretic peptide method in patients with heart failure: a multisite study. Clin Chem 2004;50:867-73.
18. Sokoll LJ, Baum H, Collinson PO, Gurr E, Haass M, Luthe H, et al. Multicenter analytical performance evaluation of the Elecsys proBNP method. Clin Chem Lab Med 2004;42;965-72.
19. Storti S, Prontera C, Emdin M, Passino C, Prati P, Fontani G, et al. Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide method: comparison with a point of care testing method. Clin Chem Lab Med 2004;42:1178-85.
20. Clerico A, Prontera C, Emdin M, Passino C, Storti S, Poletti R, et al. Analytical performance and diagnostic accuracy of immunometric methods for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin Chem 2005;51:445-7.
21. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. Analytical performance and diagnostic accuracy of a full-automated electrochemiluminescent method for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric methods for brain natriuretic peptide and atrial peptide. Clin Chem Lab Med 2004;42:37-44.
22. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AHB, Tate J, et al. on behalf of the committee on standardization of markers of cardiac damage of the IFCC. Quality specifications for B-type natriuretic peptide methods. Clin Chem 2005;51:486-93.
23. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices; approved guideline. NCCLS guideline EP5-A. Wayne, PA: NCCLS, 1999.
24. National Committee for Clinical Laboratory Standards. Evaluation of the linearity of quantitative measurement procedures: a statistical approach; proposed guideline. NCCLS guideline EP6-A. Wayne, PA: NCCLS, 1986.
25. National Committee for Clinical Laboratory Standards. Interference testing in clinical chemistry: proposed guideline. NCCLS guideline EP7-P. Wayne, PA: NCCLS, 1986.
26. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J Clin Chem Clin Biochem 1983; 21:709-20.
27. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:307-10.
28. Wu AH, Smith A, Wieczorek S, Mather JF, Duncan B, Withe M, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628-31.
29. Pagani F, Stefini M, Panteghini M. Biological variation in serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) [abstract]. Clin Chem 2003;49:A34.
30. Bruins S, Fokkema MR, Romer JWP, Dejongste MJ, Van Der Dijs FPL, Van Den Ouweland JMW, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-8.
31. Galvani M, Ottani F, Oltrona L, Ardissimo D, Gensini G, Maggioni AP, et al. N-Terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004;110:128-34.
32. Van Der Merwe D, Henly R, Lane G, Field R, Frenneaux M, Dunstan F, et al. Effect of different sample types and stability after blood collection of N-terminal pro-B-type natriuretic peptide as measured with Roche system. Clin Chem 2004;50:779-80.
33. Collison PO, Bames SC, Gaze DC, Galasko G, Senior LR. Analytical performance of the N-terminal pro B type natriuretic peptide (NT-proBNP) method on the Elecsys 1010 and 2010 analyzers. Eur J Heart Fail 2004;6:365-8.
34. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004;42:942-4.
35. Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M, Giannessi D. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 2002;40:371-7.
36. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
37. Nageh T, Chin D, Cooke JC, Meehan N, Monaghan MJ, Sherwood RA. Interpretation of plasma brain natriuretic peptide concentration may require adjustment for patient's age. Ann Clin Biochem 2002;39:151-3.
38. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254-8.